title: Flushing and haemodynamic responses to vasopressin peptides in the rhesus monkey.
abstract: 1. The mechanism of the flushing, hypotension and tachycardia associated with i.v. administration of desGlyd(CH2)5D-Tyr(Et)VAVP (SK&F 101926; 25 micrograms kg-1) and the selective V2 antidiuretic agonist, desamino-8-D-arginine vasopressin (dDAVP; 3 micrograms kg-1) was studied in ketamine-anaesthetized rhesus monkeys. 2. The flushing associated with SK&F 101926 was reduced by pretreatment with a mast cell stabilizer and by repeated administration of peptide (within 2-4 weeks). A similar desensitization to dDAVP-associated flushing was observed on repeated administration. 3. Treatment with dDAVP also resulted in reduced SK&F 101926-associated flushing. 4. The hypotension associated with SK&F 101926 was not affected by pretreatment with a mast cell stabilizer. A similar degree of hypotension was observed with repeated administration of either SK&F 101926 or dDAVP. 5. The tachycardia associated with SK&F 101926 was reduced by pretreatment with a mast cell stabilizer or repeated administration of SK&F 101926. Repeated administration of dDAVP, however, resulted in an enhanced tachycardia. 6. Indomethacin (5 mg kg-1 i.v.) did not alter the flushing or the hypotension associated with the administration of either SK&F 101926 or dDAVP, but resulted in an enhanced tachycardia to SK&F 101926. 7. Administration of a selective V1 vasopressor antagonist did not result in flushing, hypotension or tachycardia. 8. It was concluded that the flushing response to vasopressin-like peptides in rhesus monkeys may be due to an action on mast cells, whereas the haemodynamic responses are not, but probably involve direct vasodilator actions.
authors.affiliation: Department of Pharmacology, Smith Kline & French Laboratories, King of Prussia, PA.
authors.forename: D P
authors.initials: DP
authors.lastname: Brooks
authors.forename: P F
authors.initials: PF
authors.lastname: Koster
authors.forename: F L
authors.initials: FL
authors.lastname: Stassen
authors.forename: C R
authors.initials: CR
authors.lastname: Albrightson
authors.forename: W F
authors.initials: WF
authors.lastname: Huffman
authors.forename: M A
authors.initials: MA
authors.lastname: Wasserman
authors.forename: L B
authors.initials: LB
authors.lastname: Kinter
mesh_terms: D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology*; D004195:Disease Models, Animal; D005483:Flushing / Q000139:chemically induced* / Q000517:prevention & control; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D007213:Indomethacin / Q000494:pharmacology; D008253:Macaca mulatta; D008297:Male
chemical_list: D001127:Arginine Vasopressin; C050890:1-((beta-mercapto-beta)beta cyclopentamethylenepropionic acid)-2-(O-ethyl-Tyr)-4-Val-9-des-Gly-arginine vasopressin; D003894:Deamino Arginine Vasopressin; D007213:Indomethacin